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1534 Spada et al Clinical Gastroenterology and Hepatology Vol. 14, No. 11Colon capsule endoscopy (CCE), introduced in2006, has generated great expectations,1 but the
enthusiasm for this new, noninvasive technique able to
explore the colon without sedation and air insufﬂation
was mitigated when the ﬁrst studies were published.2,3
Compared with colonoscopy, the ﬁrst generation of CCE
was shown to be a feasible and safe imaging test of the
colon. However, sensitivity for clinically meaningful le-
sions, ie, 6 mm polyps or masses, appeared to be
suboptimal.2–4 For this reason, a second-generation
capsule (CCE-2) was developed.5,6 New technology was
implemented; in particular, the capsule frame rate
increased from 4 to 35 images per second to adequately
image the mucosa when the capsule is accelerated by
peristalsis. The angle of view also increased from 156
to 172 for each lens to cover nearly 360 of the colon
surface. The Data Recorder (DR3) was also improved
by simplifying the procedure.
For both generation capsules, ambitious claims
mostly are based on relatively few within-subject com-
parisons with colonoscopy from single centers.7 These
studies vary considerably in terms of study design,
selected population, and technical performances of the
colon capsule. Moreover, although the second generation
is believed to have higher accuracy when compared with
the ﬁrst generation of colon capsule, this assumption was
never systematically demonstrated.
A core body of evidence now exists for CCE-2, including
pivotal trials in the United States and Japan that were
recently published.8,9 These trials prompted the U.S. Food
and Drug Administration (FDA) and the Japanese Phar-
maceuticals and Medical Device Agency (PMDA) to
recently clear the device for use in these countries.
Furthermore, in 2016 the FDA further expanded the
indication for the second-generation capsule. Performing
a meta-analysis is necessary to more thoroughly under-
stand the performance of CCE-2 across varied studies and
assess its differences from the older and underperforming
CCE-1, where misconceptions may still reside around the
accuracy of the ﬁrst versus second generation.
The aim of this systematic review and meta-analysis
was to assess CCE accuracy as veriﬁed with within-
subjects colonoscopy in detecting colorectal lesions and
to compare the performance of the ﬁrst and second
generations of colon capsule.
Methods
Methods of analysis and inclusion criteria were based
on PRISMA recommendations.10
Eligibility Criteria
We considered all clinical studies (involving human
subjects) from 1966 to September 15, 2015, in which
accuracy of CCE for colorectal polyps was assessed by
using colonoscopy with histology as comparator. Animaland review studies were excluded. If there was any
suspicion of cohort overlap between studies, only the
most recent study was included.
Information Sources
Relevant original publications (in English language)
were identiﬁed in MEDLINE, EMBASE, and Cochrane Cen-
tral Register of Controlled Trials and in the abstract pub-
lications of the largest medical conferences on this topic
(Digestive Disease Week and United European Gastroin-
testinal Week). Prespeciﬁed Medical Subject Headings
(MeSH) and non-MeSH termswere used for the search and
are reported in SupplementaryMaterial. Both full texts and
abstracts were included. Abstracts were included to mini-
mize publication bias. Additional publications were iden-
tiﬁed through searching the reference lists of retrieved
articles. A full list of retrieved studies and the reason for
exclusion are in Supplementary Table 1. When further in-
formation from selected articles was needed to clarify
methodology/data of included studies, we attempted to
contact the authors (Supplementary Table 2).
Study Selection
All titles and abstracts of articles retrieved in the pre-
speciﬁed search were independently screened by 2 re-
viewers (C.H., C.S.). By using the full report of the study,
studies were evaluated for inclusion in the analysis. The
following inclusion criteria were applied: (1) use of colon
capsule, (2) detection of polyps/neoplasia as study end
point, (3) colonoscopy with histology used as reference
standard, and (4) possibility to extract data from 2  2
tables to deﬁne CCE accuracy. Exclusion criteria were (1)
inﬂammatory bowel disease–related CCE study with end
points other than sporadic neoplasia, (2) suboptimal
reference standard such as computed tomography colo-
nography or fecal tests, and (3) poor quality of data pre-
venting an adequate extraction. Any disagreements were
resolved through consensus. Data were extracted from the
included studies by 1 reviewer (C.S.) and checked by 1 of
the second reviewers (C.H., J.A.L., R.P., S.A.G., F.S.S.), and the
data were extracted into tables. Any disagreements were
resolved through discussion with a third reviewer (S.P.).
Data Collection Process and List of Items
From each article, the reviewers independently
abstracted the following information: (1) year of publi-
cation; 2) type of publication (full text/abstract); 3)
country(ies); (4) number of centers; (5) study design
(prospective/retrospective/mono-/multi-center); (6)
generation of CCE (1 vs 2); (7) polyethylene glycol (PEG)
volume administered; (8) type and volume of booster;
(9) matching rule between CCE and colonoscopy adopted
(if any); (10) availability of either or both per-patient and
per-polyp analysis; (11) timing of colonoscopy (same day
Figure 1. Flow chart of the systematic review.
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at colonoscopy; (13) number of patients enrolled/
included; (14) reasons for exclusion; (15) mean age and
(16) indications (colorectal cancer [CRC] screening,
family/personal history of colorectal neoplasia, symp-
toms, positive fecal occult blood test [FOBT], positive
imaging tests, other); (17) rate of adequate cleansing at
CCE; (18) CCE excretion rates at different timings (<8
hours, 8–10 hours, >10 hours); (19) colon transit time
(minutes) (mean/median); (20) number of patients with
any polyp size or (21)6 mm/10 mm polyps at CCE and
colonoscopy; (22) number of patients with at least 1 ade-
noma of any size or (23) 6 mm/10 mm at CCE and
colonoscopy; (24) number of patients with at least 1 sessile
serrated polyp of any size or (25)6 mm/10 mm at CCE
and colonoscopy; (26) number of patients with at least 1
invasive CRC at CCE and colonoscopy; and (27) rate of
adverse events at CCE and colonoscopy.
Risk of Bias in Individual Studies
To assess the methodological quality of the included
studies and detect potential bias, the Quality Assessment
of Diagnostic Accuracy in Systematic Reviews (QUADAS)
was used.11
Summary Measures
The primary end points of this systematic review
were (1) the per-patient sensitivity of CCE for different
categories of polyp size (6 vs 10 mm) and (2) the
per-patient sensitivity of CCE for cancer.
Data and Statistical Analysis
The standard methods recommended for the diag-
nostic accuracy of meta-analyses were used.12 The
following measures of test accuracy for different polyps
sizes were computed for each individual study: sensi-
tivity, speciﬁcity, positive likelihood ratio (PLR), negative
likelihood ratio (NLR), and diagnostic odds ratio (DOR).
The diagnostic threshold identiﬁed for each study was
used to plot a summary receiver operating characteristic
(SROC) curve.13 The area under the curve (AUC) was
calculated. The AUC is a measure of the ability to
discriminate between those with and without disease. A
value of 0.5 is no better than chance, whereas a value of
1.0 represents perfect diagnostic test discrimination;
tests with values greater than 0.80 are generally
considered to have good discerning properties. The inter-
study heterogeneity was calculated by the c2-based
Q test and the inconsistency index I2. When a signiﬁcant
Q test (P < .05 or I2 > 50%) indicated heterogeneity
among studies, the random-effects model (DerSimo-
nian–Laird method) was conducted for the meta-analysis
to calculate the pooled sensitivity, speciﬁcity, and
other related indexes of the studies; otherwise, theﬁxed-effects model (Mantel–Haenszel method) was cho-
sen. As a further assessment of threshold effect, we also
calculated the Spearman correlation coefﬁcient between
sensitivity (logit of the true-positive rate) and speciﬁcity
(logit of the false-positive rate) for each test. If threshold
effect exists, an inverse correlation appears. We consid-
ered a positive Spearman correlation coefﬁcient of >0.6
to be strong and suggestive of threshold effect.13,14 If the
value was less than 0.6, the accuracy of the tests could be
based on pooled estimates of sensitivity and speciﬁcity.
Meta-regression was performed to investigate the
source of heterogeneity within the included studies (in-
verse variance weighted). Subgroup analyses were also
performed if necessary to dissect the heterogeneity.
Because publication bias is of concern for meta-analyses
of diagnostic studies, we tested for the potential pres-
ence of this bias by using Deeks’ funnel plots. Analyses
were performed by using R software 2.15.2 (2012-10-
26).15 R Foundation for Statistical Computing, Vienna,
Austria. In every test, a two-sided P value <.05 was
considered statistically signiﬁcant.
Results
Study Selection and Characteristics of
Included Studies
The study ﬂow chart is shown in Figure 1; 14 studies
were included in the analysis. To obtain further infor-
mation, 2 authors were contacted (Supplementary
Table 2). Main characteristics of the included studies
are provided in Supplementary Tables 3 and 4.
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The studies, performed between 2006 and 2015,
varied in patient accrual from 40 to 884, with a median
of 79 participants per series (interquartile range,
59–198) (Supplementary Table 4). Overall, the total
number of enrolled patients was 2681, but 261 (9.7%)
were excluded from the original trials (mean of patients
excluded per trial, 19; median, 6; range, 0–189). Thus, in
the ﬁnal analysis, we included 14 studies with a total of
2420 participants. Across the 14 eligible studies, the
indications for endoscopy included CRC screening
(n ¼ 1261, 47%), post-polypectomy surveillance or CRC
family history (636, 24%), FOBT positivity and/or
symptoms (619, 23%), positive imaging tests (136, 5%),
and other indication (24, 1%).
Interventions
Capsule generation. Seven studies (involving 1128
patients) tested the accuracy of CCE-1, and the remaining
7 series (1292 patients) used CCE-2 (Supplementary
Table 5).
Bowel preparation and excretion. Capsule bowel
preparation and excretion rates are described in
Supplementary Table 5. The median rates of adequate
cleansing level were 78% and 81% with CCE-1 and CCE-
2 studies, respectively. The type of capsule did not
signiﬁcantly affect the excretion rate (86.7%; 95% con-
ﬁdence interval [CI], 79.3%–91.7% for CCE-1 vs 90.5%;
95% CI, 88.3%–92.4% for CCE-2; P ¼ .203).
Outcomes
Prevalence of patients with at least one 6 mm polyp
at colonoscopy was reported in 13 series including 2358
patients, and the cumulative prevalence was 24.7% (583
of 2358). Prevalence of patients with at least one 10
mm polyp was reported in 8 series (2095 patients), and
the cumulative prevalence was 12.7% (281 of 2204).
Risk of Bias Within Studies
Quality assessment of the individual studies is re-
ported in Supplementary Table 6. Patients were recruited
consecutively in 2 studies, whereas in the others a non-
consecutive recruitment prevented a reliable assessment
of the withdrawal rate. Only 2 trials included asymptom-
atic subjects (1109 patients, 41.4% of the total) who may
be considered as typically representative of a CRC
screening population,8,16 whereas the remaining 12
studies enrolled a symptomatic and/or disease-enriched
population. Colonoscopy was performed in all the
studies after CCE, with the endoscopist blinded to CCE
results. This was mainly due to the difﬁculty of reading
CCE examinations before the performance of colonoscopy,
with 2 exceptions where unblinding was performed aftercecal intubation or colonoscopy. For this reason, eventual
false negatives at colonoscopy were generally classiﬁed as
false positives at CCE, presumably underestimating CCE
accuracy. To assess CCE accuracy on the basis of colo-
noscopy results, amatching-polyp algorithm between CCE
and colonoscopy results is required.
Synthesis of Results
Diagnostic accuracy analysis: ‡6 mm polyps. Per-
patient data for 6 mm polyps could be obtained in 13 of
the 14 trials (2358 participants). The sensitivity and
speciﬁcity of CCE to detect patients with 6 mm polyps
are shown in a forest plot (Figure 2A) and in
Supplementary Table 7. There was substantial between-
study heterogeneity for both sensitivity (I2 ¼ 86.1%;
95% CI, 78%–91%; P < .0001) and speciﬁcity (I2 ¼
85.8%; 95% CI, 77.3%–91.1%; P < .0001). For full de-
tails and the SROC curve, see Supplementary Material
and Supplementary Figure 1, respectively. Signiﬁcant
values for study heterogeneity were mainly caused by 1
study16 that was atypical in respect to sensitivity. In a
sensitivity analysis (Supplementary Material and
Supplementary Figure 2), this trial was identiﬁed as an
outlier. Removal of this study reduced the amount of
heterogeneity from 86.1% to 31.5% (P ¼ .109).
Diagnostic accuracy analysis: ‡10 mm polyps. Per-
patient data for 10 mm polyps could be obtained in 10
of the 14 trials. Figure 2B displays the forest plots of the
sensitivity and speciﬁcity of CCE in these 10 studies for
the detection of 10 mm polyps. The I2 of sensitivity and
speciﬁcity were 53.4% (P < .001) and 31.3% (P ¼ .002),
respectively. The pooled estimated sensitivity and spec-
iﬁcity from the random-effects model were 81.0% (95%
CI, 66.0%–90.3%) and 96.2% (95% CI, 94.0%–97.6%),
respectively. The pooled PLR, NLR, and DOR were 18.6
(95% CI, 12.0-28.2), 0.22 (95% CI, 0.13–0.34), and 90.4
(95% CI, 44–163), respectively. Our data showed that the
SROC curve for detecting 10 mm polyps is positioned
near the desirable upper left corner, and the AUC was
0.94 (95% CI, 0.88–1.00), indicating that the level of
overall accuracy was high. Heterogeneity was mainly
caused by one large study that was atypical with respect
to sensitivity.17
Meta-regression analysis: diagnostic performance of
test for detecting ‡6 mm polyps. Because signiﬁcant het-
erogeneity was identiﬁed among included studies, a
meta-regression analysis was performed to explore the
possible covariates for the heterogeneity. The covariates
selected in the present meta-regression were geograph-
ical location (Europe compared with Asia/United States),
sample size, study design (multicenter compared with
single center), mean age of participants, study population
(only asymptomatic people vs high-risk or symptomatic
subjects), and type of CCE (second vs ﬁrst generation).
The outcomes of meta-regression are shown in Table 1.
Meta-regression including sample size, mean age,
geographical location, and study design did not yield any
Figure 2. Forest plots show per-patient sensitivity and speciﬁcity of CCE to detect 6 mm polyps (A) and 10 mm polyps (B)
with 95% CI for each individual study. In these graphs, between-study variability is also provided, showing substantial het-
erogeneity for sensitivity for both 6 mm (A) and 10 mm polyps (B).
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ysis, the earlier a study had been performed, the lower
was the performance of CCE; the sensitivity of CCE in
detecting clinically signiﬁcant polyps (6 mm in size)
increased by increasing year of publication (regression
coefﬁcient, 0.16; 95% CI, 0.02–0.30; P ¼ .021), whereas
false-positive rate decreased (regression coefﬁcient,
–0.13; 95% CI, –0.26 to 0.01; P ¼ .078). CCE showedbetter speciﬁcity in studies including only asymptomatic
subjects: regression coefﬁcient for false-positive rate,
–1.5; 95% CI, –2.3 to –0.7; P < .001). Interestingly, the
point estimate for the sensitivity did not indicate any
signiﬁcant effect (regression coefﬁcient, 0.821; 95% CI,
–0.266 to 1.91; P ¼ .139). Compared with CCE-1, there
was increased sensitivity for detection of polyps 6 mm
(regression coefﬁcient, 1.48; 95% CI, 0.89–2.08;
Table 1. Univariate Meta-regression With Random-effects Model of Logit of Observed True-positive (Polyps 6 mm) and
False-positive Rates to Sociodemographic, Methodological, and Clinical Characteristic
Variable
Coefﬁcient (sensitivity)
(95% CI) P value
Coefﬁcient (false-positive
rate) (95% CI) P value
Sample size (no. of participants, as continuous variable) 0.0 (0.003 to 0.002) .757 0.001 (0.15 to 0.001) .165
Year of the study
as continuous variable (in years) 0.16 (0.02–0.30) .021 0.13 (0.25 to 0.01) .078
as categorical (2011 or after vs before 2011) 1.10 (0.34–1.2) .004 0.4 (1.3 to 0.5) .419
Geographical location (Europe vs Asia/USA) 0.588 (1.697 to 0.521) .299 0.395 (0.685 to .0.521) .474
Study design (multicenter vs single center trial) 0.164 (0.91 to 1.23) .765 0.511 (1.475 to 0.452) .298
Study population (asymptomatic vs symptomatic and/or
disease-enriched population)
0.821 (0.266 to 1.908) .139 1.471 (2.250 to 0.692) <.001
CCE type (second vs ﬁrst generation) 1.49 (0.89–2.08) <.001 0.14 (1.1 to 0.81) .776
Mean age of participants as continuous variable (years) 0.089 (0.261 to 0.082) .307 0.019 (0.166 to 0.128) .800
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coefﬁcient, –0.14; 95% CI, –1.1 to 0.90; P ¼ .776) with
second-generation systems. Finally, multivariate analysis
that was based on type of systems, disease prevalence,
and year of study publication was also performed. In the
multivariate analysis, disease prevalence remained
signiﬁcantly associated with test speciﬁcity (regression
coefﬁcient for false positivity rate, –1.4; 95% CI, –2.5 to
0.28; P ¼ .015) and CCE type with test sensitivity
(regression coefﬁcient for sensitivity, 1.6; 95% CI,
0.7–2.6; P ¼ .001).
To conﬁrm results of meta-regression, 2 subgroup
analyses were performed. As shown in Figure 3A, the test
sensitivity for 6 mm polyps in studies that used CCE-2
was 86% (95% CI, 82%–89%) (I2 ¼ 0%; P ¼ .896),
whereas the sensitivity in studies that used CCE-1 was
58% (95% CI, 44%–70%) (I2 ¼ 65.0%; P ¼ .009). The
overall speciﬁcities of CCE-2 and CCE-1 were similar:
88.1% (95% CI, 74.2%–95.0%) vs 85.7% (95% CI,
80.2%–90.0%) (P ¼ .695). The pooled PLR, NLR, and
DOR for CCE-2 were 7.9 (95% CI, 3.7–16.1), 0.16 (95%
CI, 0.12–0.21), and 50.5 (95% CI, 20.3–107.0), respec-
tively. The corresponding ﬁgures for CCE-1 were 3.7
(95% CI, 3.0–4.4), 0.51 (95% CI, 0.40–0.64), and 7.4
(95% CI, 5.0–10.4). Speciﬁcity of CCE was inﬂuenced by
the prevalence of disease; the overall speciﬁcity of CCE
was 94.7% (95% CI, 91.0%–96.1%) among asymptom-
atic subjects (2 trials, n ¼ 920), and it was 83.7% (95%
CI, 81.0%–85.7%) among high-risk/symptomatic pa-
tients (P < .001) (Figure 4). The pooled PLR, NLR, and
DOR in the asymptomatic subjects were 18.7 (95% CI,
10.3–31.8), 0.17 (95% CI, 0.10–0.26), and 113 (95% CI,
63.6–182), respectively. The corresponding ﬁgures for
disease-enriched populations were 4.0 (95% CI, 3.0–5.2),
0.4 (95% CI, 0.3–0.5), and 10.7 (95% CI, 6.4–16.6),
respectively.
Meta-regression analysis: diagnostic performance of
test for detecting ‡10 mm polyps. According to meta-
regression analysis, sensitivity for detecting 10 mm
polyps differed according to the generation of CCE
(regression coefﬁcient, 1.7; 95% CI, 1.0–2.5; P < .001)
(Figure 3B). The effect on speciﬁcity was not signiﬁcant(regression coefﬁcient, 0.85; 95% CI, –0.16 to 1.9;
P ¼ .100). Speciﬁcity among studies assessing only
asymptomatic populations was higher than that among
studies assessing disease-enriched populations (regres-
sion coefﬁcient, –0.88, 95% CI, –1.9 to 0.09; P ¼ .075),
whereas sensitivity was similar (regression coefﬁcient,
0.4; 95% CI, –1.3 to 1.9; P ¼ .664). Also, sensitivity of
CCE tended to change with year of publication (coefﬁ-
cient regression, 0.21; 95% CI, –0.02 to 0.45; P ¼ .069).
Estimates were consistent with results of subgroup an-
alyses. Sensitivity and speciﬁcity for CCE-2 were 87%
(95% CI, 81%–91%; I2 ¼ 0%; P ¼ .994) and 95.3%
(95% CI, 91.5%–97.5%; I2 ¼ 67.0%; P ¼ .006), respec-
tively, and 54% (95% CI, 29%–77%; I2 ¼ 76.2%;
P ¼ .015) and 97.4% (95% CI, 96.0%–98.3%; I2 ¼ 0%;
P ¼ .543) for CCE-1, respectively. The overall speciﬁcity
was 98% (95% CI, 94%–99%; I2 ¼ 56.5%; P ¼ .364)
for the subgroup of studies assessing asymptomatic
individuals, and it was 95% (95% CI, 91.0%–97.0%;
I2 ¼ 59.5%; P ¼ .014) for those including also high-risk/
symptomatic patients (P ¼ .080). Multivariate analysis,
which was based on year of publication, disease preva-
lence, and system type, indicated that the association
between CCE type and test sensitivity (regression coef-
ﬁcient, 1.8; 95% CI, 0.88–2.7; P < .001) and that be-
tween disease prevalence and speciﬁcity (regression
coefﬁcient, –1.3; 95% CI, –1.9 to –0.6; P ¼ .004) were
statistically signiﬁcant.
Histology
Insufﬁcient studies reported on the histology of 6
mm and 10 mm polyps to warrant assessment in the
meta-analysis. This prevented separate subanalysis
according to polyp histology (ie, adenomas, serrated, etc).
Cancer
Of the 14 trials, 10 provided data about cancer
detection. There were no missed cancers (n ¼ 11) in
series where CCE-2 was used (cumulative per-patient
Figure 3. Subgroup anal-
ysis: sensitivity of second-
vs ﬁrst-generation systems
for polyps 6 mm (A) and
10 mm (B). Events, TPs
([true positives], ie, pa-
tients with polyps 6 mm
[A] or 10 mm [B]) found at
CCE; Total, TPs at the
reference standard (colo-
noscopy). Proportion, per-
centage of TPs found at
CCE among patients with
endoscopically proven
polyps 6 mm (A) or 10
mm (B).
November 2016 First and Second Generation of CCE 1539sensitivity, 100%), whereas 6 of the 26 proven cancers
were missed in series that used CCE-1 (cumulative
sensitivity, 77%; P ¼ .349).Publication Bias Evaluation
Evaluation by both Egger’s test (P ¼ .652) and Begg’s
test (P ¼ .693) did not show evidence of publication bias
for log DOR. This result was conﬁrmed by inspection of
the funnel plots, which were all symmetrical for theinvestigated diagnostic measures (sensitivity, speciﬁcity,
positive predictive value, negative predictive value,
likehood ratio (LR)þ, LR data not shown and accuracy;
Figure 5).Adverse Events
Overall, 245 adverse events were reported in 13 of
the 14 included trials in 2367 patients, corresponding to
a cumulative rate of 10.4%. Of these 245 adverse events,
Figure 4. Subgroup anal-
ysis: speciﬁcity for detect-
ing polyps 6 mm or larger
among series involving
only asymptomatic sub-
jects vs enriched-disease
population. Events, TNs
([true negatives], ie, pa-
tients without polyps
6 mm) found at CCE;
Total, TNs at the reference
standard (colonoscopy).
Proportion, percentage of
TNs found at CCE among
patients without endo-
scopically proven polyps
6 mm.
1540 Spada et al Clinical Gastroenterology and Hepatology Vol. 14, No. 11208 occurred in 2142 patients related to bowel preparation
(cumulative rate, 208 of 2142; 9.7%). Data on the adverse
events related to CCE or CC were available in 12 of 13 trials
including 1822 patients. There were 6 adverse events in
these 1822 patients related to the capsule, yielding a cu-
mulative rate of 0.33%. There were 20 adverse events
related to colonoscopy in 12 of 14 studies in 2047 patients,
corresponding to a cumulative rate of 0.98%. Most adverse
events appeared to be mild/moderate (ie, nausea, vomiting,
abdominal pain), with the exception of 6 cases that were
related to colonoscopy and/or polypectomy: colonicFigure 5. Funnel plot for CCE accuracy (after logit trans-
formation) of individual trials against their standard errors.perforation (n¼ 3), post-polypectomy bleeding (n¼ 2), and
cardiac failure (n ¼ 1). None of the 6 CCE-related adverse
events was severe.
Discussion
There is now a core body of literature for CCE, with
the recent publication of second-generation pivotal trials
in the United States and Japan.8,9 This is resulting in
global expansion of device acceptance, including FDA and
PMDA clearance, and a new user base. Understanding the
performance of CCE-2 across varied studies and the
differences from CCE-1 was assessed herein, which is
critical in this changing and growing CCE environment
and will help to guide practitioners regarding device
usage. According to our per-patient analysis that used
colonoscopy as the gold standard, CCE-2 sensitivity for
both 6 mm and 10 mm polyps was adequate and was
substantially improved as compared with CCE-1. We also
showed that CCE speciﬁcity was higher for 10 mm vs
6 mm polyps and higher for CRC screening, compared
with disease-enriched populations.
The results of our meta-analysis are relevant for the
following reasons. First, the sensitivity values achieved
by CCE-2, ie, 86% and 87% for 6 mm and 10 mm
polyps, represent a clinically relevant improvement
compared with the corresponding values shown by CCE-
1, ie, 58% and 54% for 6 mm and 10 mm polyps.
Although the >85% sensitivity of CCE-2 may be
considered clinically adequate for a noninvasive
screening or diagnostic test because it is equal or supe-
rior to that of computed tomography colonography,18 the
<70% sensitivity shown by CCE-1 is regarded as
November 2016 First and Second Generation of CCE 1541suboptimal. The relatively high sensitivity of CCE-2 for
6 and 10 mm polyps is clinically strengthened by the
100% detection of the 11 invasive carcinomas present in
the included series.
Second, the association between polyp size and CCE
speciﬁcity is clinically relevant. The increase in positive
LR from 5.6 to 18.6 with an increase from a 6-mm to a
10-mm cutoff may be useful to reduce the rate of post-
CCE colonoscopies. This is in line with the 10-mm cut-
off adopted in pragmatic trials of computed tomography
colonography.19,20 The fact that most advanced colo-
rectal neoplasia is actually harbored in 10 mm rather
than in 6 mm polyps would further support the
adoption of such a cutoff in clinical practice.21
Third, when considering that clinical importance of
speciﬁcity is inversely related with prevalence of disease,
the higher CCE speciﬁcity in screening asymptomatic
subjects as compared with disease-enriched populations
is clinically reassuring. One possible explanation is the
overcalling of ﬁndings in disease-enriched populations vs
the screening setting. Furthermore, unblinding of CCE
results before colonoscopy was performed in a large
screening trial, which may have improved the speciﬁcity
in this population.8 Overall, our estimates of speciﬁcity
and positive LRs are likely to represent a worst-case
scenario for CCE, because post-CCE colonoscopy was
performed in most of the studies without unblinding of
CCE results. It is possible that a false-negative colonos-
copy may have been incorrectly classiﬁed as a false-
positive CCE, artiﬁcially worsening CCE speciﬁcity. The
higher speciﬁcity of CCE for 10 mm as compared with
6 mm lesions would support this argument, when
considering the association between missed lesions at
colonoscopy and polyp size in tandem colonoscopy
studies.22,23
The main strength of our analysis is that colonoscopy
with histology was the gold standard in all series.
Despite the fact that colonoscopy is hampered by a
signiﬁcant miss rate, especially for 6–9 mm polyps,22,23
it remains the most accurate diagnostic technique
available for colorectal polyps. The main limitation of
our meta-analysis is represented by the high level of
heterogeneity present in our estimates. However, we
were able to identify one article with atypical estimates
that was mainly responsible for such heterogeneity.17
Fortunately, there was no heterogeneity in the accu-
racy of CCE-2 for 6 mm and 10 mm polyps. Second,
our estimates that were based on polyp detection may
be only considered as a proxy for neoplasia detection.
However, this is inherent in any noninvasive test that
does not allow for biopsies, such as CCE and computed
tomography colonography.24 Third, the design of our
analysis excluded the assessment of CCE uptake from
general or clinical populations, as other studies did.25,26
However, accuracy values are independent from uptake
values.
Colonoscopy remains the gold standard for CRC
screening. Although CCE-2 had good accuracy, inparticular for the screening population and polyps 10
mm, the device remains somewhat less sensitive than
colonoscopy for the detection of clinically signiﬁcant
polyps. Thew95% speciﬁcity of CCE-2 for large polyps
and asymptomatic individuals appears largely equiva-
lent to that of colonoscopy, although it was lower in the
diagnostic population for polyps 6 mm. The 81% rate
of adequate cleansing for CCE-2 was lower than would
be expected with colonoscopy, likely in part related to
the inability of the capsule to irrigate. Similarly, the
exam completion rate was 90.5%; again this is some-
what lower than the cecal intubation rate expected for
colonoscopy. The results of this analysis also showed
that CCE is an extremely safe procedure, with no
serious adverse events in more than 2000 patients,
which may be a competitive advantage over
colonoscopy.27
In comparison with colonoscopy, CCE-2 has both
advantages and disadvantages. In general, colonoscopy
remains superior to CCE-2 for several reasons. It has the
ability for intervention, whereas CCE is a diagnostic
modality; there is some uncertainty related to the most
appropriate polyp size cutoff for referral to colonoscopy
after positive CCE; 2 recent publications raised uncer-
tainty regarding CCE-2 accuracy for sessile serrated
polyps, with the larger trial showing a low sensitivity and
the other suggesting robust detection8,9; the bowel prep
is slightly more aggressive for CCE-2 vs colonoscopy, and
the capsule cannot remedy substandard bowel prepara-
tion through irrigation; and the completion rate is
somewhat lower for CCE. Advantages of CCE-2 include its
noninvasive and safe nature, absence of sedation, the
potential to be appealing to a subset of patients who
might not otherwise consider screening, and the ability
for patients to perform many normal daily activities
while undergoing colonic evaluation. For these reasons,
it logically holds that the use of CCE-2 would be most
suitable in those who are unwilling to undergo colo-
noscopy or in whom colonoscopy is not feasible.
In conclusion, our study showed adequate detection
of both 6 mm and 10 mm colorectal polyps by CCE-2
was signiﬁcantly improved vs CCE-1. When coupled with
its safety proﬁle, the colon capsule may be a suitable
alternative to colonoscopy for colon polyp and CRC
screening and diagnosis, particularly in patients unwill-
ing to undertake colonoscopy or for those in whom it is
technically not feasible.
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Medical Subject Headings Terms
(“colon”[MeSH Terms] OR “colon”[All Fields] OR
“rectum”[MeSH Terms] OR “rectum”[All Fields] OR “col-
orectal”[All Fields]) AND (“colonic polyps”[MeSH Terms]
OR (“colonic”[All Fields] AND “polyps”[All Fields]) OR
“colonic polyps”[All Fields] OR (“colon”[All Fields] AND
“polyp”[All Fields]) OR “colon polyp”[All Fields] OR
“polyps”[MeSH Terms] OR “polyps”[All Fields] OR “pol-
yp”[All Fields] OR “lesion”[All Fields] OR “Adenoma”
[Mesh] OR “adenoma”[All Fields] OR “adenomatous”[All
Fields] OR “neoplasia”[All Fields] OR “Neoplasms”
[Mesh]) AND (“colon capsule endoscopy”[All Fields] OR
“capsule endoscopy”[All Fields] OR “Capsule Endo-
scopy”[Mesh]) AND English[lang].
Per-patient Sensitivity and Speciﬁcity for
Polyps >5 Millimeters
The Spearman rank correlations between the logistic
transformations (logit) of the true-positive rate plotted
against the logit of the false-positive rate were –0.038
(95% CI, –0.6 to 0.5), indicating that a threshold effect is
unlikely to contribute to heterogeneity. The pooled
(random-effects model) estimated sensitivity was 74.4%
(95% CI, 61.0%–84.0%), and the pooled speciﬁcity was
87.1% (95% CI, 80.3%–91.1%). The I2 of PLR, NLR, and
DOR were 8.9% (P ¼ .625), 11.5% (P ¼ .349), and 7.9%
(P ¼ .72), respectively. The overall PLR and NLR were
5.6 (95% CI, 3.6–8.3) and 0.32 (95% CI, 0.22–0.43). The
pooled DOR ratio was 18.7 (95% CI, 8.9–35.5). The SROC
curve is shown in Supplementary Figure 1, which in-
dicates sensitivity versus 1-speciﬁcity (ie, false-positive
rate) of individual studies. The area under the SROC
curve was 0.87 (95% CI, 0.80–0.94).
Per-patient Sensitivity and Speciﬁcity for
Polyps >5 Millimeters
The pooled estimated sensitivity and speciﬁcity from
the random-effects model were 81.0% (95% CI, 66.0%–
90.3%) and 96.2% (95% CI, 94.0%–97.6%). The pooled
PLR, NLR, and DOR were 18.6 (95% CI, 12.0–28.2), 0.22
(95% CI, 0.13–0.34), and 90.4 (95% CI, 44–163),
respectively.
Our data showed that the SROC curve for detecting
10 mm polyps is positioned near the desirable upper
left corner, and the AUC was 0.94 (95% CI, 0.88–1.00),
indicating that the level of overall accuracy was high.Heterogeneity among studies was mainly caused by one
large study that was atypical in respect to sensitivity.16
After this study was removed (in a sensitivity analysis),
sensitivity of the test was 84% (95% CI, 74%–91%).Inﬂuence Case Analysis
Methods. An outlying case may not be of much
consequence if it exerts little inﬂuence on the results.
However, if the exclusion of a study from the analysis
leads to considerable changes in the model, then the
study may be considered to be inﬂuential. Case deletion
diagnostics known from linear regression (eg, Belsley
et al, 1980; Cook and Weisberg, 1982) can be adapted to
the context of meta-analysis to identify such studies. The
following diagnostic measures for the random-effects
model were computed by using R software (Wolfgang
Viechtbauer. Conducting meta-analyses in R with the
metafor package. Journal of Statistical Software
2010;36:1–48.)
1. Externally standardized residuals
2. Cook’s distances
3. the estimates of tau2 when each study is removed
in turn
4. the test statistics for (residual) heterogeneity when
each study is removed in turn.
Results. Inﬂuence analysis for the random-effects model:
success rate. The data used in this study were taken from
13 clinical trial articles that investigated diagnostic per-
formance of CCE for detecting clinically signiﬁcant polyps
(6 mm or larger in size). The outcome of this analysis
was the sensitivity, ie, the proportion of true-positive
patients correctly identiﬁed by CCE among positive
patients at reference standard.
The results from the random-effects model indicate a
signiﬁcant amount of residual heterogeneity (I2 ¼
86.1%; 95% CI, 78.0%–91%; P < .001). To detect
possible outliers, a variety of outlier and inﬂuential case
diagnostics were computed (Viechtbauer and Cheung,
2010). Results of the inﬂuence analysis are shown in
Supplementary Figure 2. On the basis of the Cook’s dis-
tance (Supplementary Figure 2), we found the following
study to be the most inﬂuential in the meta-analysis:
Sacher-Huvelin et al, 2010. This study was identiﬁed as
outliers having the highest standardized residuals
(Supplementary Figure 2). Removal of this study reduced
the amount of heterogeneity from 81.4% to 31.5%. After
reﬁtting the model and leaving this study out, the pooled
sensitivity was 79.6% (95% CI, 69%–91%).
Supplementary Figure 1. SROC curve is plotted. The sum-
mary joint sensitivity and speciﬁcity point with conﬁdence
region is also plotted: sensitivity, 73%; 95% CI, 62.3%–
81.5% and false-positive rate, 0.134; 95% CI, 0.09–0.19). The
conﬁdence region is based on the CI around the summary
point and indicates that on the basis of the available data, we
would expect the “real value” to be within that region 95% of
the time.
Supplementary Figure 2. Results of outlier and inﬂuence
case analysis for random-effects model of CCE sensitivity for
clinically signiﬁcant polyps (6 mm). Shown is a plot of
standardized residuals (top) and Cook’s distances (bottom)
for the random-effects model. Removal of study 4 would
reduce the amount of heterogeneity quite a bit and increase
the precision of the estimated average outcome from the
random-effects model.
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1. Koulaouzidis A, Plevris JN. Colon capsule endoscopy for detection of polyps and cancers: a step
closer to non-invasive colon screening? J R Coll Physicians Edinb 2011;41:124–125.
Not ﬁtting the inclusion
criteria
2. Adler SN, Hassan C, Metzger Y, et al. Second-generation colon capsule endoscopy is feasible in
the out-of-clinic setting. Surg Endosc 2014;28:570–575.
Not ﬁtting the inclusion
criteria
3. Adrián-de-Ganzo Z, Alarcón-Fernández O, Ramos L, et al. Uptake of colon capsule endoscopy vs
colonoscopy for screening relatives of patients with colorectal cancer. Clin Gastroenterol Hepatol
2015;13:2293–2301.
Not ﬁtting the inclusion
criteria
4. Romero C, Rodriguez de Miguel C, Serradesanferm A, et al. Pillcam colon capsule for colorectal
cancer screening: a prospective and comparative study with colonoscopy. Gastroenterology
2015;148:S759.
Included
5. Spada C, Riccioni ME, Hassan C, et al. PillCam colon capsule endoscopy: a prospective,
randomized trial comparing two regimens of preparation. J Clin Gastroenterol 2011;45:119–124.
Included
6. Spada C, Hassan C, Cesaro P, et al. Prospective trial of PillCam colon capsule (CCE) vs CT-
colonography (CTC) in the evaluation of patients with incomplete conventional colonoscopy (CC):
an interim analysis. Gastrointest Endosc 2013;77:AB163.
Not ﬁtting the inclusion
criteria and duplication
7. Spada C, Hassan C, Ingrosso M, et al. A new regimen of bowel preparation for PillCam colon
capsule endoscopy: a pilot study. Dig Liver Dis 2011;43:300–304.
Included
8. Spada C, Hassan C, Munos-Navaz MA, et al. Second-generation Pillcam colon capsule compared
with colonoscopy. Dig Liver Dis 2011;43:S115.
Duplication
9. Spada C, Hassan C, Munoz-Navas MA, et al. Second-generation Pillcam colon capsule compared
with colonoscopy. Gastrointest Endosc 2011;73:AB141.
Duplication
10. Spada C, Hassan C, Adler SN, et al. Flat colorectal lesions at PillCam colon capsule endoscopy
(CCE). Gastrointest Endosc 2013;77:AB175.
Not ﬁtting the inclusion
criteria and duplication
11. Spada C, Hassan C, Marmo R, et al. Accuracy of colon capsule endoscopy as compared to
colonoscopy in the detection of colorectal polyps: systematic review and meta-analysis. Dig Liver
Dis 2010;42:S65–S66.
Not ﬁtting the inclusion
criteria
12. Postgate AJ, Fraser C, Fitzpatrick A, et al. Pillcam colon capsule endoscopy compared to
colonoscopy in detection of colon polyps and cancers: interim analysis of a prospective multicentre
trial. Gut 2008;57:A47.
Duplication
13. Alvarez Urturi C, Dedeu JM, Bessa X, et al. Colon capsule endoscopy compared to colonoscopy for
familial screening of colorectal cancer. Gastrointest Endosc 2011;73:AB300.
Not ﬁtting the inclusion
criteria
14. Health Quality Ontario. Colon capsule endoscopy for the detection of colorectal polyps: an
evidence-based analysis. Ont Health Technol Assess Ser 2015;15:1–39.
Not ﬁtting the inclusion
criteria
15. Rondonotti E, Mandelli G, Borghi C, et al. PillCam Colon Capsule 2® in the setting of colorectal
cancer screening program: preliminary results of the comparison with a new integrated reference
standard. Gastrointest Endosc 2013;77:AB466.
Duplication
16. Rondonotti E, Borghi C, Mandelli G, et al. Accuracy of capsule colonoscopy and computed
tomographic colonography in individuals with positive results from the fecal occult blood test. Clin
Gastroenterol Hepatol 2014;12:1303–1310.
Included
17. Rondonotti E, Mandelli G, Borghi C, et al. Pillcam Colon Capsule 2 in the setting of colorectal
cancer screening program: preliminary results of the comparison with a new integrated reference
standard. Dig Liver Dis 2013;45:S136.
Duplication
18. Eliakim R, Fireman Z, Gralnek IM, et al. Evaluation of the Pillcam Colon Capsule in the detection of
colonic pathology: results of the ﬁrst multicenter, prospective, comparative study. Endoscopy
2006;38:963–970.
Included
19. Eliakim R, Yassin K, Niv Y, et al. Prospective multicenter performance evaluation of the second-
generation colon capsule compared with colonoscopy. Endoscopy 2009;41:1026–1031.
Included
20. Costamagna G, Spada C, Riccioni ME, et al. Evaluation of bowel preparation and procedure for
Pillcam-Colon Capsule: an interim analysis. Gastrointest Endosc 2009;69:AB375.
Duplication
21. Giday S, Pickett-Blakely O, Mullin GE. Colon cancer diagnosed by capsule endoscopy. Clin
Gastroenterol Hepatol 2008;6:A34.
Not ﬁtting the inclusion
criteria
22. Takamaru H, Kakugawa Y, Mori G, et al. Evaluation of the ability to visualize colorectal polyps with
colon capsule endoscopy. Gastrointest. Endosc 2015;81:AB381.
Not ﬁtting the inclusion
criteria
23. Hagel AF, Gabele E, Raithel M, et al. Colon capsule endoscopy: detection of colonic polyps
compared with conventional colonoscopy and visualization of extracolonic pathologies. Can J
Gastroenterol Hepatol 2014;28:77–82.
Not ﬁtting the inclusion
criteria
24. Herrerías-Gutiérrez JM, Argüelles-Arias F, Caunedo-Álvarez A, et al. PillCamColon Capsule for the
study of colonic pathology in clinical practice: study of agreement with colonoscopy. Rev Esp
Enferm Dig 2011;103:69–75.
Not ﬁtting the inclusion
criteria
25. Holleran G, Leen R, O’Morain C, et al. Colon capsule endoscopy as possible ﬁlter test for
colonoscopy selection in a screening population with positive fecal immunology. Endoscopy
2014;46:473–478.
Included
26. Clara Luz MG, Sanchez Chavez X, Mejia Cuan LA, et al. Colon capsule endoscopy compared to
conventional colonoscopy in Mexican population. Gastrointest Endosc 2012;75:AB349–AB350.
Not ﬁtting the inclusion
criteria
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27. Baltes P, Bota M, Albert JG, et al. PillCam Colon2 after incomplete colonoscopy: a prospective
multi-center study. Gastrointest Endosc 2014;79:AB584.
Not ﬁtting the inclusion
criteria
28. Pilz JB, Portmann S, Peter S, et al. Colon capsule endoscopy compared to conventional
colonoscopy under routine screening conditions. BMC Gastroenterol 2010;10:66.
Included
29. Eliakim R. The PillCam Colon Capsule for colon cancer screening: comparison between the ﬁrst-
and second-generation capsules. Hospital Practice 2010;38:110–116.
Not ﬁtting the inclusion
criteria
30. Rex DK, Adler SN, Aisenberg J, et al. Accuracy of capsule colonoscopy in detecting colorectal
polyps in a screening population. Gastroenterology 2015;148:948–957.
Included
31. Oka S, Tanaka S, Saito Y, et al. Evaluation of the clinical efﬁcacy of colon capsule endoscopy in the
detection of lesion of the colon: prospective multicenter study in Japan. Gastrointest Endosc
2004;79:AB170–AB171.
Duplication
32. Suchanek S, Voska M, Majek O, et al. The efﬁciency of colonic capsule endoscopy in detection of
colorectal polyps and cancers comparing to colonoscopy: multicenter, prospective cross over
study. Gastrointest Endosc 2013;77:AB433–AB434.
Duplication
33. Suchanek S, Majek O, Tacheci I, et al. The efﬁciency of colonic capsule endoscopy in detection of
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Supplementary Table 2. Contacts With Authors for Additional Information
Author Type of publication Country(ies) No. of centers Study design
Romero,27 Gastroenterology 2015 (abstract) Abstract Spain 1 Prospective, multicenter
Holleran,28 Endoscopy 2014 Full article Ireland 1 Prospective, single center
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Supplementary Table 3.Main Characteristics of the Included Series
Author
Type of
publication Country(ies)
No. of
centers Study design
Eliakim,4 Endoscopy 2006 Full article Israel 3 Prospective, multicenter
Schoofs,30 Endoscopy 2006 Full article Belgium 1 Prospective, single center
Van Gossum,3 N Engl J Med 2009 Full article Belgium, Spain, France,
Italy, United Kingdom,
Germany
8 Prospective, multicenter
Sacher-Huvelin,17 Aliment Pharmacol Ther 2010 Full article France 16 Prospective, multicenter
Pilz,31 BMC Gastroenterol 2010 Full article Switzerland 1 Prospective, single center
Spada,32 Dig Liver Dis 2011 Full article Italy 3 Prospective, multicenter
Spada,33 J Clin Gastroenterol 2011 Full article Italy 1 Prospective, single center
Eliakim,6 Endoscopy 2009 Full article Israel 5 Prospective, multicenter
Spada,5 Gastrointest Endosc 2011 Full article Europe 8 Prospective, multicenter
Holleran,29 Endoscopy 2014 Full article Ireland 1 Prospective, single center
Rex,8 Gastroenterology 2015 Full article USA (10), Israel (6) 16 Prospective, multicenter
Suchanek,16 Gastrointest Endosc 2015 (abstract) Abstract Czech Republic 5 Prospective, multicenter
Rondonotti,34 Clin Gastroenterol Hepatol 2014 Full article Italy 1 Prospective, single center
Romero,28 Gastroenterology 2015 (abstract) Abstract Spain 1 Prospective, single center
Supplementary Table 4. Patients and Indications
Author
Patients Indications (N)
No.
enrolled
No.
included
Mean
age (y)
CRC
screening
Family/personal
history Symptoms FOBT þ
Imaging
tests þ Other
Eliakim,4 Endoscopy 2006 91 84 57 39 0 20 0 24 8
Schoofs,30 Endoscopy 2006 41 36 56 17 0 24 0 0 0
Van Gossum,3 N Engl J Med 2009 332 320 58.5 0 0 208 0 112 0
Sacher-Huvelin,17 Aliment
Pharmacol Ther 2010
545 545 60 0 545 0 0 0 0
Pilz,31 BMC Gastroenterol 2010 59 56 60 23 4 26 0 0 3
Spada,32 Dig Liver Dis 2011 60 47 54 0 2 46 5 0 5
Spada,33 J Clin
Gastroenterol 2011
40 40 58.8 17 1 38 1 0 8
Eliakim,6 Endoscopy 2009 104 98 48.8 31 33 20 21 0 0
Spada,5 Gastrointest
Endosc 2011
117 109 60 25 51 38 7 0 0
Holleran,29 Endoscopy 2014 62 62 62.5 0 0 0 62 0 0
Rex,8 Gastroenterology 2015 884 695 57 884 0 0 0 0 0
Suchanek,16 Gastrointest
Endosc 2015 (abstract)
225 225 59 225 0 0 0 0 0
Rondonotti,34 Clin Gastroenterol
Hepatol 2014
54 50 59.2 0 0 0 50 0 0
Romero,28 Gastroenterology
2015 (abstract)
67 53 61.3 0 0 0 53 0 0
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Supplementary Table 5. Regimens of Preparation, Capsule Cleansing Level, and Excretions
Author C1/C2 PEG Volume, L Booster Volume
Adequate
cleansing level (%)
Excretion
rate < 8 h (%)
Excretion
rate 8–10 h (%)
Excretion
rate > 10 h (%)
Eliakim,4 Endoscopy 2006 C1 Yes 2 þ 2 NaP 30 mL þ 15 mL 84.4 NA 70 NA
Schoofs,30 Endoscopy 2006 C1 Yes 3 þ 1 NaP 45 mL þ 30 mL 88 NA 84 NA
Van Gossum,3 N Engl J Med 2009 C1 Yes 3 þ 1 NaP 45 mL þ 30 mL 72 69.1 92.8 99.7
Sacher-Huvelin,17 Aliment
Pharmacol Ther 2010
C1 Yes 3 þ 1 NaP 45 mL þ 30 mL 52 NA 91 NA
Pilz,31 BMC Gastroenterol 2010 C1 Yes 2 þ 2 NaP 45 mL þ 30 mL 81 NA NA 64
Spada,32 Dig Liver Dis 2011 C1 Yes 3 þ 1
2 þ 2
NaP 45 þ 30
30 mL þ 15 mL
78 NA 83 NA
Spada,33 J Clin Gastroenterol 2011 C1 Yes 3 þ 1 NaP
PEG
45 mL þ30 mL (NaP)
0.5 L þ 0.5 L(PEG)
35/53 (overall 42.5) NA 100/75 NA
Eliakim,6 Endoscopy 2009 C2 Yes 2 þ 2 NaP 30 mL þ 15 mL 78 81 NA NA
Spada,5 Gastrointest Endosc 2011 C2 Yes 2 þ 2 NaP 30 mL þ 25 mL 81 85 88 NA
Holleran,29 Endoscopy 2014 C2 Yes 2 þ 2 NaP
SPS
45 mL þ 30 mL (NaP)
45 mL þ 30 mL (SPS)
92 73 NA NA
Rex,8 Gastroenterology 2015 C2 Yes 2 þ 2 Suprep 6 oz þ 3 oz 80 88 91 NA
Suchanek,16 Gastrointest Endosc
2015 (abstract)
C2 NA NA NA NA 90 NA NA NA
Rondonotti,34 Clin Gastroenterol
Hepatol 2014
C2 Macrogol 3350 1 þ 1 NaP 30 mL þ 15 mL 70 NA NA 100
Romero,28 Gastroenterology
2015 (abstract)
C2 Moviprep 1 þ 1 Moviprep/
Gastrograﬁn
0.5 L þ 0.5 L/
50 þ 25 mL
79 75.5 NA 5.7
NA, not available; NaP, sodium phosphate; SPS, sodium picosulfate.
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Supplementary Table 6.Quality Assessment of Included Studies Using the 14 Items of QUADAS Tool
QUADAS item Eliakim4 Schoofs30
Van
Gossum3
Sacher-
Huvelin17 Pilz31 Spada32 Spada33 Romero28 Eliakim6 Spada5 Holleran29 Rex8 Suchanek16 Rondonotti34
1. Was the spectrum of patients
representative of the patients who will
receive the test in practice?
No No No No Yes No No No No No Yes Yes Yes Yes
2. Were selection criteria clearly
described?
Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
3. Is the reference standard likely to
correctly classify the target
condition?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
4. Is the time period between reference
standard and index test short enough
to be reasonably sure that the target
condition did not change between
the 2 tests?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
5. Did the whole sample or a random
selection of the sample receive
veriﬁcation by using a reference
standard of diagnosis?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
6. Did patients receive the same
reference standard regardless of the
index test result?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
7. Was the reference standard
independent of the index test, ie, the
index test did not form part of the
reference standard?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
8. Was the execution of the index test
described in sufﬁcient detail to permit
replication of the test?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
9. Was the execution of the reference
standard described in sufﬁcient detail
to permit its replication?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
10. Were the index test results
interpreted without knowledge of the
results of the reference standard?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
11. Were the reference standard results
interpreted without knowledge of the
results of the index test?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
12. Were the same clinical data available
when test results were interpreted as
would be available when the test is
used in practice?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
13. Were uninterpretable/intermediate
test results reported?
Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
14. Were withdrawals from the study
explained?
No No No No No No No No No No No No No Yes
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Supplementary Table 7. CCE Accuracy
Author C1/C2
Polyps any size, % Polyps 6 mm, % Polyps 10 mm, % CRC, %
Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV
Eliakim,4 Endoscopy 2006 C1 69 81 74 78 63 94 67 91 — — — — — — — —
Schoofs,30 Endoscopy 2006 C1 76 64 83 54 60 73 46 83 — — — — — — — —
Van Gossum,3 N Engl J Med 2009 C1 72 78 — — 64 84 — — 60 98 — — 74 74 — —
Sacher-Huvelin,17 Aliment Pharmacol Ther 2010 C1 58 71 73 56 39 88 47 85 35 97 52 95 60 100 60 100
Pilz,31 BMC Gastroenterol 2010 C1 79 54 63 71 50 76 20 93 — — — — — — — —
Spada,32 Dig Liver Dis 2011 C1 — — — — 100 95 78 100 100 100 100 100 — — — —
Spada,33 J Clin Gastroenterol 2011 C1 — — — — 63 87 77 78 — — — — — — — —
Eliakim,6 Endoscopy 2009 C2 — — — — 89 76 — — 88 89 — — — — — —
Spada,5 Gastrointest Endosc 2011 C2 — — — — 84 64 — — 88 95 — — 100 — — —
Holleran,29 Endoscopy 2014 C2 95 65 79 90 — — — — 89 96 89 96 100 — — —
Rex,8 Gastroenterology 2015 C2 — — — — 87 94 — — 85 97 — — 100 — — —
Suchanek,16 Gastrointest Endosc 2015 (abstract) C2 — — — — 79 97 — — 88 99 — — 100 — — —
Rondonotti,34 Clin Gastroenterol Hepatol 2014 C2 — — — — 88.2 87.8 — — 92.8 91.6 — — — — — —
Romero,28 Gastroenterology 2015 (abstract) C2 100 100 — 94 87 88 — — 88 94 — — — — — —
NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, speciﬁcity.
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